Literature DB >> 392005

Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials.

R Kahlich, J Klíma, F Cihla, V Franková, K Masek, M Rosický, F Matousek, J Bruthans.   

Abstract

The results of three serologically controlled double blind field trials in army units are presented. The evaluation of results according to morbidity, regardless of aetiology, showed a significant reduction in acute respiratory diseases (ARD) after administration of Impulsin. In the 1973 trial (901 volunteers), 22.7% of ARD cases were found in the Impulsin group contrary to 34.4% in the placebo group (P less than 0.0002). The relevant values in the 1974 trial (610 volunteers) were 19.7% and 40.7% (P less than 0.002) and in the 1975 trial (353 volunteers) 10.6% and 28.8% (P less than 0.004). The study of the immunological background in representative sets of volunteers allowed determination of the aetiology, the proportion of asymptomatic infections and possible deformation of results due to preexisting protective antibodies. Manifestation rate (MR) expressing the proportion of sick persons out of all sensitive subjects with serologically proved infection was found useful. This indicator is relatively independent of randomization and is more sensitive as compared to the incidence rate. In the 1973 trial, influenza A 2 England was prevalent, the MR of infection being 15.4% in the Impulsin group and 44.9% in the placebo group (P less than 0.0002). After elimination of persons with preinfection antibodies greater than or equal to 1:256 the corresponding values of MR were 17.6% and 46.6% (P less than 0.005), reflecting the "relatively clean effect" of Impulsin. In the 1974 trial, where influenza B Hong-Kong was prevalent, MR was 14.3% and 57.1%, respectively (P less than 0.001). Preinfection antibodies were negligible. The preliminary prophylactic index of the drug seemed to be 4.3 for combined adenoviral infections (trials 1973 and 1974 taken together). In the 1975 trial, the results of serological examination were unsatisfactory. Antibodies vs. influenza A Port Chalmers were found in 24.5% of ARD only. The differnce is aetiologically unclarified ARD was statistically significant. Although displaying a significant limitation of clinical infections, the administration of Impulsin did not seem to have any influence on the formation of antibodies.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 392005

Source DB:  PubMed          Journal:  J Hyg Epidemiol Microbiol Immunol        ISSN: 0022-1732


  15 in total

1.  Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages.

Authors:  Chenggang Zhu; Carlos Solorzano; Saurabh Sahar; Natalia Realini; Ernest Fung; Paolo Sassone-Corsi; Daniele Piomelli
Journal:  Mol Pharmacol       Date:  2011-01-13       Impact factor: 4.436

Review 2.  Fatty acid amide signaling molecules.

Authors:  Cyrine Ezzili; Katerina Otrubova; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-08-13       Impact factor: 2.823

3.  Variations of cocoon external lipids during wolf spiderlings' development.

Authors:  F Ruhland; S Schulz; Marie Trabalon
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2017-07-18       Impact factor: 1.836

4.  Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity.

Authors:  Lorenzo Di Cesare Mannelli; Alessandra Pacini; Francesca Corti; Serena Boccella; Livio Luongo; Emanuela Esposito; Salvatore Cuzzocrea; Sabatino Maione; Antonio Calignano; Carla Ghelardini
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

5.  Strategies to increase the activity of microglia as efficient protectors of the brain against infections.

Authors:  Roland Nau; Sandra Ribes; Marija Djukic; Helmut Eiffert
Journal:  Front Cell Neurosci       Date:  2014-05-22       Impact factor: 5.505

Review 6.  Palmitoylethanolamide: A Natural Compound for Health Management.

Authors:  Paul Clayton; Mariko Hill; Nathasha Bogoda; Silma Subah; Ruchitha Venkatesh
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

7.  Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical.

Authors:  Jan M Keppel Hesselink
Journal:  J Pain Res       Date:  2013-08-08       Impact factor: 3.133

Review 8.  Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold.

Authors:  J M Keppel Hesselink; Tineke de Boer; Renger F Witkamp
Journal:  Int J Inflam       Date:  2013-08-27

9.  Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases.

Authors:  Nicola Antonucci; Alessandra Cirillo; Dario Siniscalco
Journal:  Case Rep Psychiatry       Date:  2015-09-29

Review 10.  Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy.

Authors:  Linda Gabrielsson; Sofia Mattsson; Christopher J Fowler
Journal:  Br J Clin Pharmacol       Date:  2016-06-29       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.